Abstract: ObjectiveTo investigate the efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin versus cisplatin for patients with middleadvanced stage uterine cervical carcinoma.Methods180 patients with middleadvanced stage uterine cervical carcinoma were randomized into concurrent chemoradiotherapy with nedaplatin group (nedaplatin group) and concurrent chemoradiotherapy with cisplatin group (cisplatin group). The shortterm efficacy and the toxicity were observed.ResultsIn  the nedaplatin group , the shortterm response rate、the oneyear relapsefree surviva l、oneyea metastasisfree survival、the twoyear relapsefree survival、the twoyear metastasisfree survival  were 98.85%、 89.66、86.21%、85.06%和80.46% , But in the cisplatin group, the shortterm response rate、the oneyear relapsefree surviva l、oneyea metastasisfree survival、the twoyear relapsefree survival、the twoyear metastasisfree survival  were 97.60%（χ2=3.07，P＞0.05）、81.93%（χ2=3.07，P＞0.05）、83.13%（χ2=0.31，P＞0.05）、78.31%（χ2=1.30，P＞0.05）和80.72%（χ2=0.00，P＞0.05）, so there was no significant difference. The incidences of nausea and vomiting in the cisplatin group were 52.27% (grade Ⅰ～Ⅳ toxicities)，12.50% (grade Ⅲ～Ⅳ toxicities), which were higher than those in the nedaplatin group 27.27% (grade Ⅰ～Ⅳ toxicities)，6.82% (grade Ⅲ～Ⅳ toxicities)(P＜0.05), while there were no significant difference in the other toxicities such as anemia，granulocytopenia，thrombocytopenia，diarrhoea between the two groups (χ2=12.18,P＞0.05).ConclusionThe efficacy of concurrent chemoradiotherapy with  nedaplatin is the same as that of  concurrent chemoradiotherapy with cisplatin, and its toxicity is welltolerated.

Key words: Uterine cervical neoplasms, Radiotherapy, Drug therapy